secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hoth Therapeutics, Inc. (HOTH)
CIK:        0001711786
Form:       8-K
Filed at:   2026-01-16T23:59:59+00:00
Accession:  0001213900-26-004899
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Hoth Therapeutics Files Presentation Materials for Weight Loss Drug and Pipeline Meetings with US Officials
--------------------------------------------------------------------------------

- Prepared presentation for US government officials on weight loss drug HT-VA and broader therapeutics pipeline
- HT-001 for skin toxicity from cancer therapy: Phase 2a data and full PK dataset expected Q1 2026
- HT-KIT targeting mastocytosis and KIT-driven cancers: IND submission targeted for Q4 2026
- HT-ALZ Alzheimer's program: preclinical data showing improved memory and reduced neuroinflammation
- HT-VA obesity program licensed from VA; preclinical studies under CRADA initiated Q3 2025

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711786/000121390026004899/0001213900-26-004899-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711786/000121390026004899/ea0272968-8k_hoth.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-004899

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer